July 29, 2021
Article
Last influenza season was notably quiet during peaking COVID-19 cases. Experts explain what may influence risk of dueling epidemics this year.
July 16, 2021
The prophylaxis showed non-inferiority across shared serotypes with an available 13-valent vaccine in its indication-supporting data.
The designation moves the companies' PDUFA date up to January 2022, when BNT162b2 may become the first regulated COVID-19 vaccine.
June 25, 2021
The challenging search for a metric that effectively evaluates an ASP’s direct impact on appropriate antimicrobial use and improved patient outcomes.
June 24, 2021
Video
An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.
June 14, 2021
Experts suggest the vaccine, if regulated by the FDA, would benefit the US as a booster dose to combat waning immunity against emerging variants.
June 02, 2021
A prospective study suggest co-infections and secondary infections are infrequent among COVID-19 patients, warranting the need for improved stewardship.
May 30, 2021
New research from Emory show a significant difference in institutional antibiotic prescribing after education on the value of PCT testing in infected patients last year.
May 27, 2021
The newest data for the real-world assessment show the mRNA vaccine provides greater immunogenicity in persons aged 12-15 years old than in young adults.
May 24, 2021
TAK-003, from Takeda, is showing slightly improved protection among seropositive participants through its 36-month follow-up.
